Group 1 - The company has experienced significant momentum following the release of data for brepocitinib in dermatomyositis and Graves' disease, indicating strong market potential for the asset [2] - Brepocitinib is expected to be filed next year and launched in 2027, with anticipation from the Key Opinion Leader (KOL) community and patients [2] - The clinical trial for brepocitinib demonstrated strong efficacy across 10 statistically significant endpoints, marking it as one of the cleanest trials in the CFO's 25-year healthcare career [2][3]